Regulatory progress on Galderma's botulinum toxin candidate keeps competitive pressure on Allergan and Revance.
Galderma has updated the FDA on its Biologics License Application (BLA) for relabotulinum toxinA, signaling continued advancement toward potential approval. Relabotulinum is a recombinant botulinum toxin designed to offer a differentiated potency and diffusion profile compared to Botox (onabotulinumtoxinA) and Revance's DaxibotulinumtoxinA (Daxxify).
The competitive toxin market is consolidating: AbbVie's Botox dominates via Allergan Aesthetics and the Allē loyalty program; Revance holds a smaller but growing share with Daxxify's longer duration (6 months vs. Botox's 3–4 months); and Evolus' Jeuveau captures price-sensitive segments. Galderma's entry, if approved, introduces a third major player and could trigger pricing pressure across the category—similar to what occurred when Jeuveau launched in 2019.
Relabotulinum's BLA progress adds a third major toxin competitor, threatening Botox's pricing and loyalty dominance.
For practices, regulatory approval of relabotulinum would expand sourcing options and potentially unlock new rebate or loyalty structures from Galderma, though Botox's entrenched position and Allē's rebate ecosystem remain formidable barriers.
Source: original report ↗
Frequently asked questions
What is relabotulinum and how is it different from Botox?
Relabotulinum is Galderma's recombinant botulinum toxin candidate designed to offer differentiated potency and diffusion profiles compared to Botox (onabotulinumtoxinA). If FDA-approved, it will compete directly with Botox and Daxxify as a third major toxin option in the market.
When will relabotulinum be approved by the FDA?
Galderma has submitted a Biologics License Application (BLA) and provided an update to the FDA, signaling continued advancement toward approval. No specific approval date has been announced, but the regulatory progress indicates movement through the approval pipeline.
How long does Daxxify last compared to Botox?
Daxxify lasts approximately 6 months, while Botox typically lasts 3–4 months. This longer duration is one of Revance's key competitive advantages in the botulinum toxin market.
Will relabotulinum approval lower botulinum toxin prices?
Yes, relabotulinum's entry as a third major competitor could trigger pricing pressure across the category, similar to what happened when Jeuveau launched in 2019. However, Botox's entrenched market position and Allergan's Allē loyalty program remain significant competitive barriers.
What botulinum toxin options do medspa practices currently have?
Practices currently source from AbbVie's Botox (dominant market leader with Allē rebates), Revance's Daxxify (6-month duration), and Evolus' Jeuveau (price-sensitive segment). Galderma's relabotulinum would add a fourth option if approved.
How many botulinum toxin brands are on the market?
Currently three major brands compete: Botox (Allergan/AbbVie), Daxxify (Revance), and Jeuveau (Evolus). Galderma's relabotulinum would become a fourth if FDA-approved, further consolidating the competitive toxin market.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
